Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicines For Europe Proposes Revised Remodulation To EU Exclusivity Proposals

Trade Group Believes Market Exclusivity Should Face Incentive Extensions, Not Data Exclusivity

Executive Summary

Medicines for Europe proposed several alterations to the European Commission’s planted alterations to market exclusivity incentives at its recent Regulatory and Pharmacovigilance Conference in Brussels, most prominently that various proposed extensions to data exclusivity should instead be used to extend market exclusivity.

You may also be interested in...

UK Outlines Upcoming Application Rules For Generics

New legislation that will come into effect at the beginning of 2025 will change the originator products that UK generics manufacturers must refer to when applying to bring certain products to market.

‘Close The R&D Gap’ Between EU & Other Regions, EFPIA Tells Lawmakers

As EU legislators begin their discussion of the EU pharmaceutical overhaul, EFPIA has issued its formal response to the proposals, with a focus on topics such as unmet medical need, environmental risk assessments and drug shortages.

EC Says ‘Bolar Exemption’ Should Cover Pricing, Reimbursement & HTA Processes

Pricing and reimbursement processes as well as health technology assessments should be explicitly included in the procedures that can be conducted for generic and biosimilar products without infringing patent rights, according to the European Commission’s legislative revision proposals.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts